Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page
Price
Target price
€0.18

€0.18

3.130%
0.0065
3.130%
€0.65

€0.65

 
Latest predictions
€1.00
13.06.20
buy
€0.30
04.05.20
buy
Your prediction

Innocan Pharma Corp. Stock

Innocan Pharma Corp. dominated the market today, gaining €0.007 (3.130%).
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Innocan Pharma Corp. stock is not clear.

Pros and Cons of Innocan Pharma Corp. in the next few years

Pros
1
Innovative
1
Could be very worthwhile Investment >20% year
Cons
1
Higher risks for its business
Register To Post

Other discussions about Innocan Pharma Corp. Stock

New thread Forum

News

Innocan Pharma's Clinical Study in the US Indicates That More Than 90% of Participants Experienced Pain Reduction after Using Innocan's Relief &Go OTC Pain Relief Spray

 

Herzliya, Israel and Calgary, Alberta - (October - , 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the Company or Innocan), is pleased to announce today a Clinical Study,

Innocan Pharma's Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction after Using its SHIR ™ Premium CBD Facial Serum: https://www.irw-press.at/prcom/images/messages/2020/53837/Innocan_EN_PRcom.001.png
Innocan Pharma's Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction after Using its SHIR ™ Premium CBD Facial Serum

 

Herzliya, Israel and Calgary, Alberta - (October 15 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce today that it has

Innocan achieves major milestone in developing its unique CBD-loaded liposome platform technology for injectable CBD.

Herzliya, Israel and Calgary, Alberta - (October 9 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the Company or Innocan), is pleased to announce today that an animal study on

Innocan Pharma to provide a corporate update via livestream video on October 14, 2020 at 10:00am EST

Herzliya, Israel and Calgary, Alberta - (October 8, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the Company or Innocan), is pleased to announce that it will provide a

Innocan Phrama Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of its SHIRTM CBD Premium Facial Serum on Skin Hydration

 

Herzliya, Israel and Calgary, Alberta - (September 14, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the Company or Innocan), is pleased to announce today, that it has

Innocan Pharma Announces Publication of Enterprise Report by Mackie Research

Herzliya, Israel and Calgary, Alberta - September 3, 2020 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that Mackie Research Capital

Innocan to distribute its CBD line of products in Italy and Switzerland

 

Herzliya, Israel and Calgary, Alberta - (August 20, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the Company or Innocan), is pleased to announce that its wholly owned

Innocan Engages Endless Sky to Manufacture and Distribute Innocan’s CBD Cosmetic products in Canada

Herzliya, Israel and Calgary, Alberta- (August 11, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its wholly owned

Innocan's SHIRTM Beauty & Science CBD Derma Cosmetics products passed safety assessments and have been approved for marketing in the European Union

Herzliya, Israel and Calgary, Alberta- (August 6, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its SHIR™ CBD Derma Cosme